Potential therapeutic applications of decoy oligonucleotides

Current Opinion in Molecular Therapeutics

Volumn 4, Issue 2, 2002, Pages 166-170

  Tomita, Naruya ^a   Morishita, Ryuichi ^a   Tomita, Tetsuya ^a   Ogihara, Toshio ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cis element decoy; Gene therapy; Glomerulonephritis; HVJ liposome; Myocardial infarction; Restenosis; Rheumatoid anthritis; Transcription factor

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CIS ACTING ELEMENT; CYCLIN A; CYCLIN DEPENDENT KINASE 2; CYCLINE; DOUBLE STRANDED DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYC PROTEIN; PROTEIN C MYB; RETINOBLASTOMA PROTEIN; THYMIDINE KINASE; TRANSCRIPTION FACTOR E2F; OLIGONUCLEOTIDE;

ANGIOPLASTY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG SCREENING; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE TARGETING; GENE TECHNOLOGY; GENETIC TRANSFECTION; HUMAN; MOLECULAR INTERACTION; NONHUMAN; RAT; RESTENOSIS; TRANSCRIPTION REGULATION; VEIN GRAFT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; BLOOD VESSEL PROSTHESIS; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; GENE THERAPY; GLOMERULONEPHRITIS; HEART INFARCTION; HYPERTENSION; REVIEW; RHEUMATOID ARTHRITIS;

ARTHRITIS, RHEUMATOID; BLOOD VESSEL PROSTHESIS; CLINICAL TRIALS; CORONARY ARTERIOSCLEROSIS; GENE THERAPY; GLOMERULONEPHRITIS; HUMAN; HYPERTENSION; MYOCARDIAL INFARCTION; OLIGONUCLEOTIDES; HUMANS;

ANIMALIA;

EID: 0035997962     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. The inducible lac operator-repressor system is functional in mammalian cells
2. Lac repressor can regulate expression from a hybrid SV40 early promoter containing a Lac operator in animal cells
3. Strategy for functional inactivation of genes: A novel strategy for gene therapy and gene regulation analysis using transcription factor decoy oligonucleotides
4. Application of transcription factor 'decoy' strategy as means of gene therapy and study of gene expression in cardiovascular disease
5. Oligonucleotide-based gene therapy for cardiovascular disease
6. Oligonucleotide-based gene therapy for cardiovascular disease: Are oligonucleotide therapeutics novel cardiovascular drugs?
7. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo
8. Role of transcriptional cis-elements, angiotensinogen gene-activating elements, of angiotensinogen gene in blood pressure regulation
9. In vivo transfection of cis element 'decoy' against nuclear factor-κB binding site prevents myocardial infarction
10. Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor κB decoy oligodeoxynucleotides as a gene therapy
11. An oligonucleotide decoy for transcription factor E2F inhibits mesangial cell proliferation in vitro
12. In vivo administration of a nuclear factor-κB decoy suppressed experimental crescentic glomerulonephritis
13. Transcription factor decoy for NFκB inhibits TNF-α-induced cytokine and adhesion molecules subdiaphragmatic in vivo
14. Retinoblastoma protein switches the E2F site from positive to negative element
15. Transcription-factor mutations and disease
16. E1A-dependent trans-activation of the human myc promoter is mediated by the E2F factor
17. Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy
18. Interleukin-8 gene induction in the myocardium after ischemia and reperfusion in vivo
19. NFκB: A pleiotropic mediator of inducible and tissue-specific gene control
20. Activation of interleukin-6 gene expression through the NFκB transcription factor
21. Direct in vivo gene introduction into rat kidney
22. In vivo gene therapy of anti-thy 1 nephritis using E2F decoy oligonucleotide
23. In vivo direct gene transfer into articular cartilage by intraarticular injection mediated by HVJ (Sendal virus) and liposomes
24. Molecular mechanism of transcriptional activation of angiotensinogen gene by proximal promoter
25. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy; the PREVENT single-centre, randomized, controlled trial
26. Gene therapy for human bypass grafts